| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MRNA | Common Stock | Sale | -$4.5M | -45K | -2.86% | $100.01 | 1.53M | Dec 27, 2023 | Direct | F1, F2 |
| holding | MRNA | Common Stock | 4.12K | Dec 27, 2023 | By Valhalla, LLC | ||||||
| holding | MRNA | Common Stock | 152K | Dec 27, 2023 | By Trust | F3 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 15, 2023. |
| F2 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $100.00 to $100.12. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| F3 | These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. |